The Workshop Programme 2022
We are already working intensely on the Workshop Programme 2022 and will publish first details by end of September 2021.
We are hoping to welcome you at Marbach in May of 2022!
The Workshop Organizers:
Robert Hermann, MD, FCP
Amin Rostami-Hodjegan, PhD, FCP
Ping Zhao, PhD
Workshop Programme 2022
Coming soon …
| Afternoon | Individual Arrival & Check-in at Marbach Castle |
| 03:00 p.m. | Registration & Coffee |
| 04:00 p.m. | Come Together Activities |
| 07:30 p.m. | Come Together Dinner |
| 09:00 p.m. | Live Music – TBD |
| 08:00 – 08:30 a.m. | Registration & Coffee |
| 08:30 – 08:50 a.m. | Welcome Address and Introduction into the Workshop Amin Rostami |
| 08:50 – 09:25 a.m. | Keynote Lecture – The Philosophy of Drug Interactions Philip D. Hansten, PharmD, Professor Emeritus, University of Washington, USA |
| 09:25 – 09:35 a.m. | Discussion |
| Session I: Food-Drug Interactions & Beyond Chair: Amin Rostami |
|
| 09:35 – 10:00 a.m. | Gut Feeling – Proteomics of Gut Wall and Relevance to Drug Absorption and Interactions Stefan Oswald, PhD, University of Greifswald, Germany |
| 10:00 – 10:10 a.m. | Discussion |
| 10:10 – 10:35 a.m. | Can we Predict Formulation-Dependent Food-Drug Interactions? Rodrigo Cristofoletti, PhD, Assistant Professor at the Center of Pharmacometrics & Systems Pharmacology, University of Florida, Gainesville, USA. |
| 10:35 – 10:45 p.m. | Discussion |
| 10:45 – 11:10 a.m. | Coffee Break |
| 11:10 – 11:35 a.m. | Food-Drug Interactions – Considerations from the IQ Working Group and Food Effect Case Studies Tycho Heimbach, PhD, Biopharmaceutics, Sterile & Specialty Products Group, Pharmaceutical Sciences, Merck & Co., Inc., Rahway, New Jersey, USA |
| 11:35 – 11:45 a.m. | Discussion |
| 11:45 – 12:05 p.m. | Regulatory Science on Assessing Food Drug Interaction – Highlights from New FDA Guidance Rajanikanth Madabushi, PhD, Office of Clinical Pharmacology, Center for Drug Evaluation and Research, FDA, Silver Spring, MD, USA |
| 12:05 – 12:15 p.m. | Discussion |
| 12:15 – 01:45 p.m. | Lunch |
| Session II: Pharmacodynamic Interactions Chair: Robert Hermann |
|
| 01:45 – 02:10 p.m. | Common Pharmacodynamic Interactions of Clinical Importance David Juurlink; MD, PhD, FRCPC, Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada |
| 02:10 – 02:20 p.m. | Discussion |
| 02:20 – 02:45 p.m. | Revisiting Pharmacodynamic Interactions: Benefits and Watch-outs in Oncology Jin Yan Jin, PhD, Genentech, San Francisco, California, USA |
| 02:45 – 02:55 p.m. | Discussion |
| 02:55 – 03:20 p.m. | Coffee Break |
| Session III: The Final FDA Guidance Documents on Drug Interactions Chair: Amin Rostami |
|
| 03:20 – 03:45 p.m. | Introductory Lecture: What did the FDA Change when it Finalized its In Vitro Drug Interaction Guidance in January, 2020? Andrew Parkinson, PhD, XPD Consulting, Shawnee KS, USA |
| 03:45 – 03:55 p.m. | Q & A Session with all Regulatory Attendees |
| 03:55 – 04:20 p.m. | Introductory Lecture: The Final FDA Guidance on Clinical Drug Interaction Studies — Cytochrome P450 Enzyme- and Transporter-Mediated Drug Interactions. Robert Hermann, MD, Clinical Research Appliance, Gelnhausen, Germany |
| 04:20– 04:40 p.m. | Q & A Session with all Regulatory Attendees |
| 07:00 p.m. | Dinner |
| Session IV: Translational DMPK Session Chair: Amin Rostami |
|
|---|---|
| 08:50 – 9:00 | Reflections on Day 1 and Opening Remarks Day 2 |
| 09:00 – 09:25 a.m. | Liquid Biopsy, its Applications, Limitations, and Potential Role for Characterising Individual Hepatic Drug Elimination Capacity Brahim Achour, PhD, University of Manchester, UK. Appointed Assistant Professor at the Faculty of the College of Pharmacy, University of Rhode Island (URI) (from September 2021) |
| 09:25 – 09:35 a.m. | Discussion |
| 09:35 – 10:00 a.m. | Metabolic Reaction Phenotyping: Do’s and Don’ts, and the Oscar Nomination Process (is Metabolism the Best Actor or the Best Supporting Actor?) Andrew Parkinson, PhD, XPD Consulting, Shawnee KS, USA |
| 10:00 – 10:10 a.m. | Discussion |
| 10:10 – 10:35 a.m. | “SLC-Phenotyping”: Quantifying Contribution of Transporters to the Hepatic Uptake Clearance of Drugs Manthena V Varma, PhD, Pfizer, Groton, CT, USA |
| 10:35 – 10:45 a.m. | Discussion |
| 10:45 – 11:10 p.m. | Coffee Break |
| Session V: Pediatric DDIs Chair: Ping Zhao |
|
| 11:10 – 11:35 a.m. | Are Neonates and Young Infants Protected against DDIs Despite their Exposure to a Multitude of Medicines? Johannes N. van den Anker, MD, PhD, Children’s National Hospital, University Children’s Hospital Basel, University of Basel, Switzerland |
| 11:35 – 11:45 a.m. | Discussion |
| 11:45 – 12:10 a.m. | Application of Pharmacometric Approaches and Real-World Data to Characterize Drug-Drug Interactions in Infants and Children Daniel Gonzalez, PharmD, PhD, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA |
| 12:10 – 12:20 p.m. | Discussion |
| 12:20 –01:45 a.m. | Lunch |
| Session VI: Herb-Drug DDIs Chair: Ping Zhao |
|
| 01:45 – 02:10 p.m. | Herbal Drug-Drug Interactions. A Meta-Analysis and Novel Insights Ingolf Cascorbi, MD, PhD, University of Kiel, Germany |
| 02:10 – 02:20 p.m. | Discussion |
| 02:20 – 02:55 p.m. | Looking Back 2 Decades: Revisiting Clinically Relevant Drug Interactions with St. John’s Wort Veronika Butterweck, PhD, Max Zeller und Söhne, Romanshorn, Switzerland |
| 02:55 – 03:05 p.m. | Discussion |
| 03:05 – 03:30 p.m. | Translational Approaches to Untangle Herb-Drug Interactions Mary Paine, RPh, PhD, Washington State University, Spokane, Washington, USA |
| 03:30 – 03:40p.m. | Discussion |
| 03:40 – 04:05 p.m. | Coffee Break |
| Session VII: Q & A Session Day 2 Chairs: Ping Zhao & Amin Rostami |
|
| 04:05 – 04:25 p.m. | Q & A Session Involving Sessions IV – VI |
| 04:25 – 04:30 p.m. | Concluding Remarks End of Meeting & Departure |
Last Update: 23.03.2021